[1] Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161. [2] Li Y, Abudureheiyimu N, ...
[20]Ouyang Q, Yin Y, Song L, et al. SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial. 2023 ESM...
图1. HER2阳性乳腺癌按照HR状态（HR阳性和HR阴性）分层的OS 图2. HER2阳性乳腺癌按照HR状态（HR低阳性、HR中/高阳性、HR阴性）分层的OS 在HR阳性和HR阴性队列中，新发MBC患者的中位OS均长于复发性MBC患者（HR阳性：新发，未达到 vs 复发，45.1个月；HR阴性：新发，54.6个月 vs 复发，30.8个月）。在...
[18]Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 t...
[3] Chen P, Zhao S, Guo W, Shao G. Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma. Quant Imaging Med Surg 2023;13(8...
3、Jhaveri KL, Goldman JW, Hurvitz SA, et al. Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial. Journal of Clinical Oncology 2022;40:102...
故近期《Nature》子刊《Scientific Reports》的一篇研究分析了HER2低表达是否会对淋巴结阳性HR+/HER2-早期乳腺癌患者预后产生影响。 研究设计 本研究回顾性纳入了2011年1月至2019年12月期间,在日本国家癌症中心的647例淋巴结阳性HR+/HER2-原发性早期乳腺癌患者,其中HER2 0 228例,HER2低表达 419例。按复发风险分为...
[3]Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. | Journal of Clinical Oncology ...
Our results indicate thatBRCA2mutations have no significant effect on the survival of Chinese women with HR-positive/HER2-negative breast cancer.doi:10.1177/17588359241242613Pu-Chun LiYi-Fan ZhuJia-Ni PanQiao-Yan ZhuYu-Yang LiaoXiao-Wen Ding...
Breast cancer patients with high proportion of cancer stem cells (BCSCs) have poor clinical outcomes. MiRNAs regulate key features of BCSCs as oncogenes or tumor suppressors. Although hormone receptor (HR)-positive, HER2-negative breast cancers are the most common subtype, current methods are inad...